EMT is associated with, but does not drive resistance to ALK inhibitors among EML4-ALK non-small cell lung cancer

Molecular Oncology

Volumn 10, Issue 4, 2016, Pages 601-609

  Gower, Arjan ^a   Hsu, Wei Hsun ^a   Hsu, Shuo Tse ^a   Wang, Yisong ^a   Giaccone, Giuseppe ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

ALK positive NSCLC; Ceritinib; Epithelial mesenchymal transition; HSP90 inhibition; Resistance

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE INHIBITOR; AXL PROTEIN; BIOLOGICAL MARKER; CERITINIB; CRIZOTINIB; ENTRECTINIB; GANETESPIB; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; NERVE CELL ADHESION MOLECULE; TANESPIMYCIN; UNCLASSIFIED DRUG; VIMENTIN; EML4-ALK FUSION PROTEIN, HUMAN; ENZYME INHIBITOR; ONCOPROTEIN; TUMOR MARKER;

ARTICLE; CANCER PATIENT; CANCER RESISTANCE; CELL DEATH; CELL MIGRATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG SENSITIVITY; EML4 ALK FUSION GENE; EPITHELIAL MESENCHYMAL TRANSITION; FUSION GENE; IN VITRO STUDY; LUNG CANCER CELL LINE; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; TUMOR INVASION; UPREGULATION; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LUNG NEOPLASMS; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; ONCOGENE PROTEINS, FUSION; UP-REGULATION;

EID: 84948798672     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2015.11.007     Document Type: Article

References (24)

1. Crystal A., Shaw A., Sequist L., Friboulet L., Niederst M., Lockerman E., Frias R., Gainor J., Amzallag A., Greninger P., Lee D., Kalsy A., Gomez-Caraballo M., Elamine L., Howe E., Hur W., Lifshits E., Robinson H., Katayama R., Faber A., Awad M., Ramaswamy S., Mino-Kenudson M., Iafrate A., Benes C., Engelman J. Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science 2014, 346:1480-1486.
2. De Braud F., Pilla L., Niger M., Damian S., Bardazza B., Martinetti A., Pelosi G., Marrapese G., Palmeri L., Cerea G., Valtorta E., Veronese E., Sartore-Bianchi A., Ardini E., Martignoni M., Galvani A., Pearson P., Luo D., Freddo J., Siena S. Phase 1 open label, dose escalation study of RXDX101, an oral oan-trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations. J. Clin. Oncol. 2014, 32:2502. Abstract.
3. Doebele R., Pilling A., Aisner D., Kutateladze T., Lee A., Weickhardt A., Kondo K., Linderman D., Heasley L., Franklin W., Varella-Garcia M., Camidge D. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin. Cancer Res. 2012, 18:1472-1482.
4. Engelman J., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J., Lindeman N., Gale C., Zhao X., Christensen J., Kosaka T., Holmes A., Rogers A., Cappuzzo F., Mok T., Lee C., Johnson B., Cantley L., Jänne P. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.
5. Friboulet L., Li N., Katayama R., Lee C., Gainor J., Crystal A., Michellys P., Awad M., Yanagitani N., Kim S., Pferdekamper A., Li J., Kasibhatla S., Sun F., Sun X., Hua S., McNamara P., Mahmood S., Lockerman E., Fujita N., Nishio M., Harris J., Shaw A., Engelman J. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014, 4:662-673.
6. Gainor J., Varghese A., Ou S., Kabraji S., Awad M., Katayama R., Pawlak A., Mino-Kenudson M., Yeap B., Riely G., Iafrate A., Arcila M., Ladanyi M., Engelman J., Dias-Santagata D., Shaw A. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clin. Cancer Res. 2013, 19:4273-4281.
7. Gower A., Wang Y., Giaccone G. Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer. J. Mol. Med. 2014, 92:697-707.
8. Hallberg B., Palmer R. Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology. Nat. Rev. Cancer 2013, 13:685-700.
9. Jemal A., Bray F., Center M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61:69-90.
10. Katayama R., Shaw A., Khan T., Mino-Kenudson M., Solomon B., Halmos B., Jessop N., Wain J., Yeo A., Benes C., Drew L., Saeh J., Crosby K., Sequist L., Iafrate A., Engelman J. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci. Transl. Med. 2012, 120:ra17.
11. Kim H., Kim W., Choi Y., Choi C., Rho J., Lee J. Epithelial-mesenchymal transition leads to crizotinib resistance in H2228 lung cancers cells with EML4-ALK translocation. Mol. Oncol. 2013, 7:1093-1102.
12. Kwak E., Bang Y., Camidge D., Shaw A., Solomon B., Maki R., Ou S., Dezube B., Jänne P., Costa D., Varella-Garcia M., Kim W., Lynch T., Fidias P., Stubbs H., Engelman J., Sequist L., Tan W., Gandhi L., Mino-Kenudson M., Wei G., Shreeve S., Ratain M., Settleman J., Christensen J., Haber D., Wilner K., Salgia R., Shapiro G., Clark J., Iafrate A. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 2010, 363:1693-1703.
13. Lamouille S., Xu J., Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat. Rev. Mol. Cell Biol. 2014, 15:178-196.
14. Li Y., Ye X., Liu J., Zha J., Pei L. Evaluation of EML4-ALK fusion proteins in non-small cell lung cancer using small molecule inhibitors. Neoplasia 2011, 13:1-11.
15. Normant E., Paez G., West K., Lim A., Slocum K., Tunkey C., McDougall J., Wylie A., Robison K., Caliri K., Palombella V., Fritz C. The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models. Oncogene 2011, 30:2581-2586.
16. Sang J., Acquaviva J., Friedland J., Smith D., Sequeira M., Zhang C., Jiang Q., Xue L., Lovly C., Jimenez J., Shaw A., Doebele R., He S., Bates R., Camidge D., Morris S., El-Hariry I., Proia D. Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer. Cancer Discov. 2013, 3:430-443.
17. Scheel C., Weinberg R. Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links. Semin. Cancer Biol. 2012, 22:396-403.
18. Shaw A., Kim D., Mehra R., Tan D., Felip E., Chow L., Camidge D., Vansteenkiste J., Sharma S., De Pas T., Riely G., Solomon B., Wolf J., Thomas M., Schuler M., Liu G., Santoro A., Lau Y., Goldwasser M., Boral A., Engelman J. Ceretinib in ALK-rearranged non-small-cell lung cancer. N. Engl. J. Med. 2014, 370:1189-1197.
19. Shaw A., Kim D., Nakagawa K., Seto T., Crinó L., Ahn M., De Pas T., Besse B., Solomon B., Blackhall F., Wu Y., Thomas M., O'Byrne K., Moro-Sibilot D., Camidge D., Mok T., Hirsh V., Riely G., Iyer S., Tassell V., Polli A., Wilner K., Jänne P. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N. Engl. J. Med. 2013, 368:2385-2394.
20. Soda M., Choi Y., Enomoto M., Takada S., Yamashita Y., Ishikawa S., Fujiwara S., Watanabe H., Kurashina K., Hatanaka H., Bando M., Ohno S., Ishikawa Y., Aburatani H., Niki T., Sohara Y., Sugiyama Y., Mano H. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448:561-566.
21. Vaishnavi A., Capelletti M., Le A., Kako S., Butaney M., Ercan D., Mahale S., Davies K., Aisner D., Pilling A., Berge E., Kim J., Sasaki H., Park S., Kryukov G., Garraway L., Hammerman P., Haas J., Andrews S., Lipson D., Stephens P., Miller V., Varella-Garcia M., Jänne P., Doebele R. Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nat. Med. 2013, 19:1469-1472.
22. Vuoriluoto K., Haugen H., Kiviluoto S., Mpindi J., Nevo J., Gjerdrum C., Tiron C., Lorens J., Ivaska J. Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer. Oncogene 2011, 30:1436-1448.
23. Wilson F., Johannessen C., Piccioni F., Tamayo P., Kim J., Van Allen E., Corsello S., Capelletti M., Calles A., Butaney M., Sharifnia T., Gabriel S., Mesirov J., Hahn W., Engelman J., Meyerson M., Root D., Jänne P., Garraway L. A functional landscape of resistance to ALK inhibition in lung cancer. Cancer Cell 2015, 27:397-408.
24. Zhang Z., Lee J., Lin L., Olivas V., Au V., LaFramboise T., Abdel-Rahman M., Wang X., Levine A., Rho J., Choi Y., Choi C., Kim S., Jang S., Park Y., Kim W., Lee D., Lee J., Miller V., Arcila M., Ladanyi M., Moonsamy P., Sawyers C., Boggon T., Ma P., Costa C., Taron M., Rosell R., Halmos B., Bivona T. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat. Genet. 2012, 44:852-860.